Illumina, Inc. (ILMN)
After hours:
| Previous close | 216.52 |
| Open | 218.88 |
| Bid | 218.00 x 1100 |
| Ask | 224.10 x 800 |
| Day's range | 218.37 - 225.38 |
| 52-week range | 173.45 - 371.16 |
| Volume | |
| Avg. volume | 1,209,463 |
| Market cap | 35.383B |
| Beta (5Y monthly) | 1.13 |
| PE ratio (TTM) | 50.66 |
| EPS (TTM) | 4.44 |
| Earnings date | 07 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 243.50 |
- Zacks
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy?
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
Illumina Appoints Joydeep Goswami Chief Financial Officer
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Joydeep Goswami has been appointed Chief Financial Officer, effective immediately. Goswami previously served as Illumina's Chief Strategy and Corporate Development Officer and interim Chief Financial Officer. As CFO, Goswami will be responsible for the Company's financial planning and analysis, accounting, investor relations, internal audit, tax, and treasury functions. He will also con
- Zacks
Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
